Neoadjuvant Chemotherapy Followed by Interval Debulking for Advanced-Stage Endometrial Cancer: Survival Outcome Based on Surgical and Molecular Characteristics
Recommended Citation
Kheil M, Mekkaoui T, Andresan E, Fung G, Miller M, Joseph JG, Wang A, Al Asadi A, Elshaikh M, Ahmad S, Awada A. Neoadjuvant Chemotherapy Followed by Interval Debulking for Advanced-Stage Endometrial Cancer: Survival Outcome Based on Surgical and Molecular Characteristics. Curr Oncol. 2026;33(8).
Document Type
Article
Publication Date
7-27-2026
Publication Title
Curr Oncol
Keywords
Humans, Female, Endometrial Neoplasms, Neoadjuvant Therapy, Retrospective Studies, Aged, Cytoreduction Surgical Procedures, Middle Aged, Neoplasm Staging
Abstract
OBJECTIVE: To examine survival outcomes and identify clinicopathological factors associated with survival in patients with advanced-stage endometrial cancer who received neoadjuvant chemotherapy before interval debulking surgery (NACT-IDS). METHODS: A single-center retrospective cohort study was conducted of patients who were diagnosed with advanced-stage (2009 FIGO IIIB, IIIC, IV) endometrial cancer (2012-2024) and underwent NACT-IDS. Tumor response to NACT was determined with computed tomography and the RECIST criteria, and demographic, clinicopathologic, perioperative, and tumor molecular features (mismatch repair protein [MMR] status and p53 pattern) were collected from medical chart review. Association between tumor molecular features and response to NACT was determined. Primary endpoints were progression-free and overall survival, analyzed with univariate Cox and stratified Kaplan-Meier analysis. RESULTS: Of 42 consecutive patients (median age of 68 years), the majority (n = 26; 61.9%) had a partial tumor response to NACT, with only five (11.9%) having a complete response, four (9.5%) having stable disease, and seven (16.7%) having progressive disease. Most cases had no residual tumor after IDS (n = 35; 83.3%). MMR protein status was associated with the tumor response to NACT (p = 0.013), but p53 status was not. During follow-up, 24 patients died (57.1%), and 31 (73.8%) died or had disease progression. Tumor response to NACT and resection margin status were associated with progression-free survival in unadjusted analyses, but no covariate adjustment was possible with limited sample size. CONCLUSIONS: This study highlights MMR-deficiency, response to NACT, and surgical resection status as clinicopathologic features of interest for future studies of prognostic factors and alternative therapies in advanced-stage endometrial cancer.
Medical Subject Headings
Humans; Female; Endometrial Neoplasms; Neoadjuvant Therapy; Retrospective Studies; Aged; Cytoreduction Surgical Procedures; Middle Aged; Neoplasm Staging
PubMed ID
42645353
Volume
33
Issue
8
